Published 30 Jun 2020

Qure.AI gets FDA clearance for head CT AI software

SHARE

https://cms.qure.ai
Qure.ai has achieved a significant milestone by receiving its inaugural US FDA 510(k) clearance for its pioneering head CT scan tool, 'qER.' This sanction enables the AI-powered solution to effectively triage radiology scans and diagnose intracranial bleeds, mass effect, midline shift, and cranial fractures. The product can uniquely detect cranial fractures and midline shifts, offering a near-comprehensive triaging solution for critical markers on regular head CT scans.
Given the high frequency of CT scans performed in the US each year, this powerful, high-grade imaging AI tool is crucial in aiding healthcare professionals to prioritize and interpret images swiftly and accurately. "The qER plays an instrumental role in providing in-depth information to doctors for making timely, crucial decisions, especially in the context of brain injuries," said Pooja Rao, Co-founder, and R&D Head at Qure.ai.
The qER suite is designed to seamlessly blend with the existing radiology workflow, prioritizing critical cases and facilitating quicker and more efficient reporting of time-sensitive health markers. Having undergone rigorous validation and testing, it is now operational at several hospitals and teleradiology providers worldwide.
In addition, Qure.ai's product range also comprises the CE-marked chest X-ray AI tool qXR and COVID-19 progression monitoring solutions for chest X-rays, which are currently in clinical use across more than 20 countries.

Share this story

Featured in

image 30.svg
image 26.svg
livemint logo.svg
image 29.svg
image 28.svg
image 31.svg
image 27.svg
image 30.svg
image 26.svg
livemint logo.svg
image 29.svg
image 28.svg
image 31.svg
image 27.svg